Promises from drug makers to control persistent increases in drug costs seem to last only as long as it is politically expedient to make them. To counteract this behavior, the Trump administration has floated proposals such as promoting competition from generic drugs and changing Medicare drug-purchase policies. Some experts are not ruling out new regulations and laws to address pharma prices.  Kaiser Health News